333 related articles for article (PubMed ID: 33793216)
1. From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
Abdel-Halim M; Sigler S; Racheed NAS; Hefnawy A; Fathalla RK; Hammam MA; Maher A; Maxuitenko Y; Keeton AB; Hartmann RW; Engel M; Piazza GA; Abadi AH
J Med Chem; 2021 Apr; 64(8):4462-4477. PubMed ID: 33793216
[TBL] [Abstract][Full Text] [Related]
2. Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.
Abdel-Halim M; Tinsley H; Keeton AB; Weam M; Atta NH; Hammam MA; Hefnawy A; Hartmann RW; Engel M; Piazza GA; Abadi AH
Bioorg Chem; 2020 Nov; 104():104322. PubMed ID: 33142429
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
[TBL] [Abstract][Full Text] [Related]
4. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.
Zhang T; Lai Z; Yuan S; Huang YY; Dong G; Sheng C; Ke H; Luo HB
J Med Chem; 2020 Sep; 63(17):9828-9837. PubMed ID: 32794708
[TBL] [Abstract][Full Text] [Related]
7. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Reddy GL; Dar MI; Hudwekar AD; Mahajan P; Nargotra A; Baba AM; Nandi U; Wazir P; Singh G; Vishwakarma RA; Syed SH; Sawant SD
Bioorg Chem; 2019 Aug; 89():103022. PubMed ID: 31181491
[TBL] [Abstract][Full Text] [Related]
9. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.
Biswas KH; Visweswariah SS
J Biol Chem; 2011 Mar; 286(10):8545-8554. PubMed ID: 21193396
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of pyrazolo[3,4-d]pyrimidinone derivatives: Discovery of selective phosphodiesterase-5 inhibitors.
Shaaban MA; Elshaier YAMM; Hammad AH; Farag NA; Hassan Haredy H; AbdEl-Ghany AA; Mohamed KO
Bioorg Med Chem Lett; 2020 Aug; 30(16):127337. PubMed ID: 32631538
[TBL] [Abstract][Full Text] [Related]
11. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G.
Tinsley HN; Gary BD; Keeton AB; Zhang W; Abadi AH; Reynolds RC; Piazza GA
Mol Cancer Ther; 2009 Dec; 8(12):3331-40. PubMed ID: 19996273
[TBL] [Abstract][Full Text] [Related]
12. Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.
Corbin JD; Zoraghi R; Francis SH
Cell Signal; 2009 Dec; 21(12):1768-74. PubMed ID: 19665054
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5.
Gong X; Wang G; Ren J; Liu Z; Wang Z; Chen T; Yang X; Jiang X; Shen J; Jiang H; Aisa HA; Xu Y; Li J
Bioorg Med Chem Lett; 2013 Sep; 23(17):4944-7. PubMed ID: 23867165
[TBL] [Abstract][Full Text] [Related]
14. Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors.
El-Gamil DS; Ahmed NS; Gary BD; Piazza GA; Engel M; Hartmann RW; Abadi AH
Arch Pharm (Weinheim); 2013 Jan; 346(1):23-33. PubMed ID: 23307609
[TBL] [Abstract][Full Text] [Related]
15. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
Corbin JD; Francis SH
Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors.
El-Sharkawy LY; El-Sakhawy RA; Abdel-Halim M; Lee K; Piazza GA; Ducho C; Hartmann RW; Abadi AH
Arch Pharm (Weinheim); 2018 May; 351(5):e1800018. PubMed ID: 29656464
[TBL] [Abstract][Full Text] [Related]
17. Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach.
Ongaro A; Zagotto G; Memo M; Gianoncelli A; Ribaudo G
Nat Prod Res; 2021 May; 35(10):1648-1653. PubMed ID: 31140295
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors.
Ahmed NS; Gary BD; Tinsley HN; Piazza GA; Laufer S; Abadi AH
Arch Pharm (Weinheim); 2011 Mar; 344(3):149-57. PubMed ID: 21384413
[TBL] [Abstract][Full Text] [Related]
19. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
Giovannoni MP; Vergelli C; Biancalani C; Cesari N; Graziano A; Biagini P; Gracia J; Gavaldà A; Dal Piaz V
J Med Chem; 2006 Aug; 49(17):5363-71. PubMed ID: 16913726
[TBL] [Abstract][Full Text] [Related]
20. Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme.
D'Amours MR; Granovsky AE; Artemyev NO; Cote RH
Mol Pharmacol; 1999 Mar; 55(3):508-14. PubMed ID: 10051534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
